Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | CASP6 | P55212 | 1/20 | 0.31 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.30 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10000564 | 0.85 | MEN1 (0.36) | MEN1KMT2AKDM4EGPR3AKT1 | |
| SCHEMBL10027989 | 0.82 | CTDSP1 (0.38) | MEN1KMT2AKDM4EGPR3IDO1 | |
| SCHEMBL10000548 | 0.81 | CYP1A2 (0.37) | MEN1KMT2AKDM4EGPR3IDO1 | |
| SCHEMBL10000580 | 0.78 | KDM4E (0.39) | NQO1MEN1KMT2AKDM4EIDO1 | |
| SCHEMBL10000559 | 0.77 | PDK2 (0.38) | NQO1MEN1KMT2AKDM4E | |
| SCHEMBL10000552 | 0.76 | CYP2A6 (0.38) | MEN1KMT2AKDM4EGPR3AKT1 | |
| SCHEMBL10000570 | 0.75 | KMT2A (0.43) | NQO1MEN1KMT2AKDM4ECASP6 | |
| SCHEMBL21226337 | 0.74 | KDM4E (0.38) | MEN1KMT2AKDM4EGPR3AKT1 | |
| SCHEMBL10028042 | 0.73 | MAPT (0.41) | MEN1KMT2A | |
| SCHEMBL24349334 | 0.73 | KDM4E (0.37) | MEN1KMT2AKDM4EGPR3AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150340628-A1 | METAL COMPLEX COMPOUND AND ORGANIC LIGHT EMITTING DIODE DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO LTD (KR) | 2015-11-26 | — | — | US | disclosed |
| US-20150340628-A1 | METAL COMPLEX COMPOUND AND ORGANIC LIGHT EMITTING DIODE DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO LTD (KR) | 2015-11-26 | — | — | US | disclosed |
| US-9096529-B2 | Metal complex compound and organic light emitting diode device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2015-08-04 | — | — | US | disclosed |
| US-9096529-B2 | Metal complex compound and organic light emitting diode device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2015-08-04 | — | — | US | disclosed |
| US-20120012824-A1 | METAL COMPLEX COMPOUND AND ORGANIC LIGHT EMITTING DIODE DEVICE INCLUDING THE SAME | SAMSUNG MOBILE DISPLAY CO., LTD. (KR) | 2012-01-19 | — | — | US | disclosed |
| US-20120012824-A1 | METAL COMPLEX COMPOUND AND ORGANIC LIGHT EMITTING DIODE DEVICE INCLUDING THE SAME | SAMSUNG MOBILE DISPLAY CO., LTD. (KR) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150340628-A1 | METAL COMPLEX COMPOUND AND ORGANIC LIGHT EMITTING DIODE DEVICE INCLUDING THE SAME | AP1M1, MT-CO1, AP2M1 | NQO1 830/4885MEN1 123/4885KMT2A 1392/4885 |
| US-20120012824-A1 | METAL COMPLEX COMPOUND AND ORGANIC LIGHT EMITTING DIODE DEVICE INCLUDING THE SAME | AP1M1, MT-CO1, AP2M1 | NQO1 830/4885MEN1 123/4885KMT2A 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.